Litigation Follows OTC Eye Drops Recall Due To Bacteria Strain Not Previously Seen In US
Complaints Against EzriCare, Delsam, Aru Pharma Follow US Warning To Manufacturer In India
Following a recall earlier in February of EzriCare’s and Delsam’s OTC artificial tears due to potential bacterial contamination, plaintiffs’ bar steps in with first of what may be multiple lawsuits. CDC says drug-resistant strain of Pseudomonas aeruginosa bacteria not previously seen in US.
You may also be interested in...
FDA Recalls For Dec. 25, 2013
Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
CIR Panel’s ‘Ethereal’ Role In Cosmetics Regulation Not Clarified By MoCRA
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.
Petition To US FDA For Using NMN In Supplements Reminds Agency Of Its Reversal On NAC
Natural Products Association and Alliance for Natural Health USA petition FDA to reconsider its stance on beta-nicotinamide mononucleotide. Excluding NMN from use in supplements “adversely affects the entire dietary supplement stakeholder community,” petition says.